Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Madhu Yelameli

Interventional Pain Medicine Columbia, TN Medical Doctor

NPI 1942305461 CMS profile 269553

1040 N. James Campbell Blvd., Ste. 108, Columbia, TN 38401

Open in the dashboard

General payments

$11,964

291 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Madhu Yelameli of Columbia, TN is reported in the CMS Open Payments database as having received $11,964 across 291 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,561 59
2024 General $1,750 81
2023 General $694 34
2022 General $971 23
2021 General $4,452 34
2020 General $1,061 26
2019 General $1,476 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Madhu Yelameli
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Madhu Yelameli were reported at $1,561. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Madhu Yelameli Interventional Pain Medicine median Middle half National median
2019 $1,476 $684 $216–$2,079 $163
2020 $1,061 $382 $122–$1,109 $114
2021 $4,452 $552 $167–$1,554 $132
2022 $971 $605 $187–$1,924 $149
2023 $694 $671 $195–$1,915 $160
2024 $1,750 $684 $206–$1,837 $164
2025 $1,561 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $5,904 134 payments
  2. Abbott Laboratories $2,419 78 payments
  3. Nevro Corp. $1,014 27 payments
  4. Flowonix Medical Incorporated $513 2 payments
  5. Nalu Medical, Inc. $380 9 payments
  6. Painteq LLC $288 8 payments
  7. Globus Medical, Inc. $247 4 payments
  8. Vertiflex, Inc. $224 3 payments
  9. Stimwave Technologies Incorporated $212 5 payments
  10. Saluda Medical Americas, Inc. $167 1 payment
  11. Other $597 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,408 286 payments
  2. Consulting Fee $3,200 1 payment
  3. Entertainment $221 1 payment
  4. Travel and Lodging $136 3 payments
Products named General payments · program years 2019–2025
  1. GENERAL PAIN MANAGEMENT $3,491 5 payments
  2. WaveWriter Alpha Prime 16 $1,865 111 payments
  3. Proclaim Family of SCS IPGs $1,213 36 payments
  4. Senza $530 15 payments
  5. Prometra II $513 2 payments
  6. PROCLAIM Neuromodulation $436 12 payments
  7. PROCLAIM Structural Heart $382 11 payments
  8. Nalu Neurostimulation System $380 9 payments
  9. Omnia $361 7 payments
  10. PAINTEQ $288 8 payments
  11. Other $2,638 76 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

2,661

Median for Interventional Pain Management: 1,220

Drug cost

$81,080

Median for Interventional Pain Management: $39,344

Branded share of claims

51.8%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 641 $18,628
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 556 $14,866
Buprenorphine Generic 42 $14,325
Linzess Linaclotide Brand 16 $8,101
Gabapentin Generic 395 $3,939
Pregabalin Generic 155 $3,889
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 36 $3,488
Xtampza Er Oxycodone Myristate Brand 12 $3,045
Oxycodone Hcl Generic 153 $2,859
Lidocaine Generic 27 $1,749

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$141,333

Of which drugs: $187

Medicare patients

303

Average age 68

Services billed

2,968

176 women, 127 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 38%
Depression 36%
COPD 32%
Ischemic heart disease 29%
Chronic kidney disease 26%
Heart failure 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 108 1,651 $140

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

291 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record